Fermenta Biotech (FBL) has signed a definitive agreement with Aurigene Pharmaceutical Services (APSL), a stepdown subsidiary of Dr Reddy’s Laboratories (DRL). In this arrangement, FBL will exclusively license its proprietary biocatalytic technology for synthesis of Molnupiravir and supply its enzyme Candida Antarctica B Lipase (CAL B) to APSL, and APSL will exclusively procure the enzyme from FBL.
Molnupiravir API manufactured by APSL will be utilized by DRL for its formulation. Additionally, APSL can also supply the API manufactured through this technology to other formulators of Molnupiravir, a COVID-19 drug that has recently received emergency use approval from the Food and Drugs Authority and Drugs Controller General of India.
Fermenta Biotech (formerly known as DIL) is engaged in the business of research support services through their subsidiary Research Support International Ltd. (RSIL), manufacture and marketing of enzymes and chemicals through their subsidiary Fermenta Biotech (FBL).
